Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.36 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.36 |
| ▸ | NPY1R | P25929 | 2/20 | 0.36 |
| ▸ | NPY4R | P50391 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803170 | 0.87 | NRP1 (0.42) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL26419823 | 0.87 | NRP1 (0.42) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL30452201 | 0.87 | NRP1 (0.43) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL20694547 | 0.86 | NRP1 (0.46) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL20694549 | 0.84 | MMP1 (0.35) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL24716410 | 0.84 | NRP1 (0.45) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL22872708 | 0.84 | NRP1 (0.54) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL30416793 | 0.84 | NRP1 (0.46) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL22803169 | 0.84 | NRP1 (0.45) | NRP1OPRM1OPRK1EPHA2GRB2 | |
| SCHEMBL29571627 | 0.82 | NRP1 (0.54) | NRP1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021003050-A2 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | NRP1 716/4885OPRM1 1622/4885OPRK1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.